Novo Nordisk and telehealth company Hims & Hers have reached an agreement ending their recent legal conflict over GLP-1 weight-loss drugs. The two companies will now collaborate to distribute FDA-approved medications Wegovy and Ozempic through Hims & Hers’ platform.
The dispute began when Hims & Hers planned to offer a lower-cost, off-brand version of Wegovy, prompting Novo Nordisk to file a patent-infringement lawsuit. Novo argued that the proposed product was an unauthorized, untested version of semaglutide. Shortly after the lawsuit was filed, Hims & Hers withdrew its off-brand plans, a move influenced by an FDA warning regarding restrictions on key ingredients used in compounded GLP-1 products.
While compounding of drugs is allowed when there is a shortage, the FDA determined in 2024 that GLP-1 medications were no longer in short supply. Some companies had continued using compounding exceptions for customized prescriptions, which became a central point of the dispute.
Under the new partnership, Hims & Hers will sell both oral and injectable versions of Wegovy and Ozempic starting later this month. The company will discontinue advertising compounded GLP-1 products, while Novo Nordisk has reserved the right to pursue legal action in the future if needed.
The announcement was well-received by the market, with Hims & Hers shares rising more than 36 percent and Novo Nordisk stock seeing modest gains.
Disclaimer: This article summarizes recent industry news and regulatory developments. It is not intended to provide medical, legal, or business advice. Readers should consult official regulatory guidance and qualified professionals for decision-making.
Source:
Moeller, M. (2026, March 13th). Novo Nordisk Ends Lawsuit, Forms Distribution Deal With Hims & Hers. American Med Spa Association. https://americanmedspa.org/news/novo-nordisk-ends-lawsuit-forms-distribution-deal-with-hims-hers
